Search

everythinglearnresearchcommunity

for

Search:↓

Combining PRS with TAFR is promising for treating complex fistulas, with most patients achieving long-term healing.

Lack of 5α-Reductase type 1 can lead to insulin resistance and liver problems.

PRMT5 inhibitors effectively fight adenoid cystic carcinoma in salivary glands.

Platelet-rich plasma can temporarily inhibit some drug-resistant bacteria in diabetic foot infections.

TTNPB helps turn stem cells into neural stem cells, improving depression-like behaviors in rats.

Blocking 5α-reductase can reduce sleep deprivation-related behavioral issues in rats.

ERG increases SOX9, promoting prostate cancer growth and invasion.

Blocking mTORC1 activity could increase hair pigmentation and potentially reverse greying.

Combining Ficlatuzumab and Gefitinib can cause severe hair loss.

SARMs may be an effective treatment for a certain type of breast cancer by blocking cancer growth and spread.

Blocking GPR91 can help prevent and reverse hair loss in androgenetic alopecia.

ARL15 is important for fat cell development and the release of the hormone adiponectin.

Sprouty and FGF balance is crucial for normal feather shape and size.

Some prostate cancers have gene changes that may affect treatment with certain drugs.

Pro-Ile could be used in cosmetics to improve skin, hair growth, and healing.

Flammulina velutipes polysaccharide helps the immune system fight tumors by activating certain pathways.

Environmental factors affect reproductive traits by altering the SRD5A1 gene.

5αR inhibitors help slow early prostate cancer cell growth, suggesting combined treatments are needed.

Platelet factor 4 slows down hair growth and could make hair loss treatments more effective if removed.

The antibody 005-C04 blocks prolactin receptors, causing reversible infertility, impaired lactation, and hair regrowth in female mice.

MK-0773 is a moderate inhibitor of the SRD5A2 enzyme.

More research needed to confirm finasteride as standard treatment for FFA.

Targeting 5α-reductase type 1 may help manage Tourette-like symptoms.

Tildrakizumab significantly improved recalcitrant lichen planopilaris and frontal fibrosing alopecia.

Targeting NETs may help reduce fibrosis in Crohn's disease.

A new peptide, FOL-005, may help treat excessive hair growth by reducing a hair growth promoter, FGF7.

Platelet-released growth factors can reduce inflammation in joint disease.

Topical ruxolitinib cream may help treat frontal fibrosing alopecia.